ALKPositive Lung Cancer Treatment Market by Drugs (Crizotinib, Alectinib,Ceritinib, and Brigatinib), by Distribution Channel (Hospital Pharmacies,Retail Pharmacies, and Clinics), and by Geography (North America, Europe, AsiaPacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, andOpportunity Analysis 2018 – 2026
ALK positive lung cancertreatment is used for people suffering from lung cancer with AnaplasticLymphoma Kinase (ALK) mutation (the EML4-ALK fusion gene). This gene mutationis due to gene rearrangement by fusion of two genes called as ALK andEchinoderm Microtubule-associated protein Like 4 (EML4). The ALK gene fusionwas first reported in 2007, in Non-small cell lung cancer (NSCLC) patients.
ALK Positive Lung CancerTreatment Market Drivers
New drug approvals for treatmentof ALK positive lung cancer is expected to drive growth of the market. Forinstance, in August 2018, China National Drug Administration (CNDA) approvedAlecensa (alectinib) of F. Hoffmann-La Roche Ltd., for treatment of ALK-positivelung cancer. Moreover, CNDA granted marketing authorization for Alecensa(alectinib), as monotherapy treatment for patients with anaplastic lymphomakinase (ALK)-positive and advanced non-small cell lung cancer (NSCLC).
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2201
ALK Positive Lung Cancer TreatmentMarket Restraints
Development of rapid resistanceto drugs is expected to limit growth of the ALK positive lung cancer treatmentmarket. For instance, according to an Oncology Live February 2018 report, majorchallenge in drug development is rapid growth in resistance, which isresponsible for slow patient recovery from disease. Moreover, according to anarticle published in Cancers journal, in August 2017, the mechanisms forresistance in drugs is tyrosine kinase mutations, and Epidermal Growth FactorReceptor (EGFR) activation. These bypass mechanisms of resistance areaggravating tumor cells, which in turn is restraining growth of the market.
ALK Positive Lung Cancer TreatmentMarket – Regional Analysis
On the basis of region, theglobal ALK positive lung cancer treatment market is segmented into NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa. NorthAmerica region is expected to witness significant growth in the market, owingto increasing number of clinical trials operating in the U.S. For instance, TPTherapeutics, Inc., is undergoing clinical trial for TPX-0005 drug for treatingALK mutations. The study is expected to complete in December 2021.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/alk-positive-lung-cancer-treatment-market-2201
Asia Pacific region is expectedto witness the significant growth in the market, owing to increasing use oftobacco and smoking leading to lung cancer. According to an article published in Eastern Journal of medical Sciences2017, lung cancer contributes around 6.8% of all cancers in India, representingthe significant burden of lung cancer on country, which is contributing towardsthe cancer morbidity and mortality.
Key players operating in ALKpositive lung cancer treatment market include F. Hoffmann-La Roche Ltd., PfizerInc., Novartis AG, TP Therapeutics, Inc., Bristol-Myers Squibb Company, and EliLilly and Company.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2201
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
